LSIPR 50 2018: Patrick Leahy
Patrick Leahy was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the government and policy section, as LSIPR reports.
LSIPR 50 2018: Raymond Chen and Kathleen O’Malley
Raymond Chen and Kathleen O’Malley were selected in the LSIPR 50 2018 publication for their influence on the life sciences industry. They featured in the government and policy section, as LSIPR reports.
LSIPR 50 2018: Scott Gottlieb
Scott Gottlieb was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the government and policy section, as LSIPR reports.
LSIPR 50 2018: The entrepreneurial bug
At Flagship Pioneering, Aram Adourian, partner, knowledge management, uses his skills to leverage internal and external knowledge and informatics across the breadth of the company’s research activities, as he tells LSIPR.
LSIPR 50 2018: Backing the innovators
Josh Makower, partner at venture capital investor New Enterprise Associates, explains to LSIPR the firm’s role in supporting medtech innovation, his sweet spot when it comes to projects, and how to balance what is medically relevant with commercial viability.
The future of precision medicine part 2: data is king
In the area of precision medicine, there are questions surrounding what data is needed, how it is used, what it should look like and what concerns there are for patients and society, as Daniel Lim of Kirkland & Ellis reports.
LSIPR 50 2018: An agent of change in healthcare
Healthcare investment yields the best returns when focusing on its core aims and forging strong partnerships, James Flynn, managing partner of Deerfield, tells LSIPR.
Will the EPO’s Enlarged Board hear the Broad’s CRISPR case?
As the Broad Institute faces a formidable task in defending its revoked CRISPR patent claims in a pending appeal at the EPO, European academics Jakob Wested, Timo Minssen, and Esther van Zimmeren are wondering whether some of the issues might be referred to the Enlarged Board of Appeal.
LSIPR 50 2018: Personalised medicine: the way forward
BMS’s teams are working to answer key questions and more intimately understand the interplay between the immune system and cancer, Paul Golian, vice president and assistant counsel of IP at BMS, tells LSIPR.
Searching for variant sequences with pinpoint accuracy
The world of sequence variation IP is complicated and confusing, and fraught with legal risk, but there is a solution, as Ellen Sherin of GQ Life Sciences reports.
